Associate Vice President for Research,
Research Director, Biosecurity Research Institute (BRI)
B.Sc. (HONS) 1980 King’s College, London, UK
Ph.D. 1985 U. Reading, UK.
Fellow 1992 Royal Entomological Society
Peine Professor of Biosecurity,
Professor, Diagnostic Medicine & Pathobiology,
Kansas State University.
Editor-in-Chief, Vector-Borne & Zoonotic Diseases.
Tel: 785 532 1333
Fax: 785 532 0973
Cell: 785 341 9004
I joined Kansas State University in July 2011 as the Associate Vice President for Research, and the Research Director of the Biosecurity Research Institute (BRI). As a Professor in College of Veterinary Medicine’s Department of Diagnostic Medicine & Pathobiology I am committed to the development of new educational and research opportunities that will allow our students to successfully compete for, and pursue diverse and exciting careers. I will be working with others to achieve “K-State 2025” by growing our interdisciplinary biosecurity research programs, leading our interdisciplinary agrosecurity initiatives and developing collaborative research with public and private-sector groups from the United States and overseas. An important aspect of my work will be to work with K-State faculty, local and federal Government agencies to expand biosafety, biosecurity and biocontainment educational programs that will be available for students.
I am currently Editor-in-Chief of the internatinal journal Vector-Borne & Zoonotic Diseases, and have recently been appointed to the Editorial Board of Biosecurity and Bioterrorism. Biodefense Strategy, Practice and Science. I am a member of the Executive Council of the American Society of Tropical Medicine and Hygiene, Chairman of the Society’s Education Committee, ex-Chairman of the Policy and Advocacy Committee, a member of the Membership Committee, the Subcommittee on Arbovirus Laboratory Safety (SALS) and the Subcommittee on the Evaluation of Arthropod-borne Status (SEAS). As a past Chairman of the American Committee for Medical Entomology, I helped to develop containment guidelines for both vectors and the agents they transmit at different biosafety levels.
At the University of Texas Medical Branch, I was the Director of the Experimental Pathology Graduate Program. I have therefore had the opportunity to mentor numerous students. Recent graduates from my laboratory at UTMB have been employed at CDC Puerto Rico, the Institute Pasteur in Paris, the University of North Carolina, and at UC Berkeley.
My philosophy and commitment to develop collaborations for the benefit of all parties, is the key to my research success. Through networking with national public and private-sector entities, and international pharmaceutical companies I interface with senior personnel to developed collaborative multidisciplinary scientific investigations and research programs that includes: vector biology, infectious diseases, immunology, and vaccine development. The ability to offer researchers from other Institutes the opportunities to conduct research in complex biocontainment research facilities with appropriate security has resulted in a history of success with respect to obtaining competitive federal funding.
The fundamental philosophy underlying my scientific career is to leverage and coordinate specific expertise and understanding, to empower individuals for personal growth so that they realize their full potential, and to develop collaborative projects that bring together complimentary resources and disciplines. The facilities and the individuals with whom I have had the privilege to work have resulted in a very satisfying ongoing research program. With competitive funding from varied sources over the years, I have directed my group’s multidisciplinary research that encompasses many aspects of vector-borne viruses, with my particular interests focusing on mosquito-virus-vertebrate interactions. Using wild type and genetically engineered chikungunya, Sindbis, o’nyong nyong, West Nile, and yellow fever viruses we have been examining fundamental aspects of virus-vector interactions. Several recent projects have involved vaccine development and evaluation, including genetic modification, vector competence tests and non-human primate experiments. Our research on a new chikungunya virus (CHIKV) vaccine (Nature Medicine, 2010) was preceded by a long standing interest in this virus that began before the ongoing epidemic that has recently infected over 2M people. Our development of patented infectious clones of this CHIKV has placed us at the forefront of research on this virus. We have distributed these research tools to other groups in an effort to better understand the epidemic.
My group at UTMB have collaborated with colleagues at Notre Dame, Tulane, the University of Pittsburg, with support from the National Institutes of Health, the Bill and Melinda Gates Foundation; and also work with scientist from Pharmaceutical companies. A recent interest has developed from the realization that during biting, an arthropod secretes substances that not only influence pathogen transmission, but also determine the severity of the disease. In collaboration with Drs. Lynn Soong, Stephen Wikel, Bob Tesh, and Saravanan Thangamani at UTMB, we have identified some of the molecules and mechanisms that are involved in this fascinating phenomenon.
Recent Publications (2010-2011)
Colpitts, T.M., Cox, J., Vanlandingham, D.L., Feitosa, F., Cheng, Kurscheid, S. Wang,P, Krishnan, M.N., Higgs, S., Fikrig, E Colpitts et al " 2011. Alterations in the Aedes aegypti transcriptome during infection with West Nile, dengue and yellow fever viruses" PLoS Pathogens (in press)
McGee, C.E., Tsetsarkin, K.A., Guy, B., Lang, J., Plante, K., Vanlandingham, D.L., Atasheva, S., Frolov, I., & Higgs, S. 2011. Stability of Yellow Fever Virus under Recombinatory Pressure as Compared with Chikungunya Virus PLoS ONE 6(8): e23247. doi:10.1371/journal.pone.0023247
Tsetsarkin, K.A., McGee, C.E. & Higgs, S. 2011. Chikungunya virus adaptation to Aedes albopictus mosquitoes does not correlate with acquisition of cholesterol dependence or decreased pH threshold for fusion reaction. Virology Journal (in press).
Van den Hurk, A., Horne, K., McGee, C., Hall-Mendelin, S., Day, A., Ryan, P., Ritchie, S., Vanlandingham, D. & Higgs, S. 2011. Vector competence of Australian mosquitoes for yellow fever virus. AM.J. Trop. Med. Hyg. (in press)
Tstesarkin, K.A., Chen, R., Leal, G., Forrester, N., Higgs, S., Huang, J. & Weaver, S.C. 2010. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc.
Nat. Acad. Sci. www.pnas.org/cgi/doi/10.1073/pnas.1018344108.
Bartholomay, L. C., et al., 2010. Pathogenomics of Culex quinquefasciatus and Meta-Analysis of Infection Responses to Diverse Pathogens. Science. 10:88-90.
Arensburger, P., et al., 2010. Sequencing of Culex quinquefasciatus establishes a platform for mosquito comparative genomics. Science 10:86-87.
Thangamani, S., Higgs, S., Ziegler, S., Vanlandingham, D., Tesh, R. & Wikel, S. 2010. Host immune response to mosquito-transmitted chikungunya virus differs from that elicited by needle inoculated virus. PloSOne. 5 e12137.
Schneider, B.S., Soong, L., Coffey, L.A., Stevenson, H.L. & Higgs, S. 2010. Aedes aegypti Saliva Alters Leukocyte Recruitment and Cytokine Signaling by Antigen-Presenting Cells during West Nile Virus Infection. PloSONE 5: e11704
Bernard, E., Solignat, M., Gay, B., Chazal, N., Higgs, S., Devaux, C & Briant, L. 2010. Endocytosis of chikungunya virus into mammalian cells: a role of clathrin and early endosomal compartments. PloSOne 5: e11479
Gardner, J., Anraku, I., Le, T.T., Larcher, T., Major, L., Roques, P., Schroder, W.A., Higgs, S.& Suhrbier, A. 2010. Chikungunya virus arthritis in adult wild-type mice. J. Virol. 84: 8021-32
Volk, S.M., Chen, R., Tsetsarkin, K.A., Adams, A.P., Garcia, T.I., Sall, A.A., Nasar, F., Schuh, A.J., Holmes, E.C., Higgs, S, A., Maharaj, P.D., Brault.C. & Weaver, S.C. 2010. Genome scale
phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and varying evolutionary rates. J. Virol. 84: 6497-504.
Skalsky, R.L., Vanlandingham, D.L., Scholle, F., Higgs S. & Cullen, B.R. 2010. Identification of microRNAs expressed in two mosquito vectors, Aedes albopictus and Culex quinquefasciatus. BMC Genomics. Feb 18;11(1):119
Girard, YA., Mayhew, G.F., Fuchs, J.F., Schneider, B.S., Li, H., Rocheleau, R.A., Christensen, B.M., Higgs, S. & Bartholomay, L.C. 2010. Transcriptome changes in Culex quinquefasciatus salivary glands during West Nile virus infection J. Med Entomol.47:421-435.
Higgs, S. & Ziegler, S. 2010. Chikungunya: A Non-human Primate Model to Evaluate the Basis of Human Disease Symptoms. J. Clinical Invest. 120: 657-660.
Akahara, W., Yang, Z., Andersen, H., Sun, S., Yoder, J.D., Kong, W.-P., Lewis, M., Higgs, S., Rossmann, M.G., Rao, S., et al.2010. A VLP vaccine for epidemic chikungunya virus protects non-human primates against infection. Nature Medicine. 16: 334-8 2010.
Kraxner, A., Tschopp, J., Higgs, S., Michault, A., Arenzana-Seisdedos, F., Colonna, M., Peduto, L., Schwartz, O., Lecuit, M. & Albert, A.L. 2010. Type I IFN controls chikungunya virus via its action on non-hematopoietic cells. J. Exp. Medicine. 207: 429-442.
Guy, B., Guirakhoo, F., Barban, V., Higgs, S., Monath, T.P. & Lang, J. 2010. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 28: 632-49.